A Phase 2 RCT Study of CX-8998 for Essential Tremor
Status:
Completed
Trial end date:
2018-07-16
Target enrollment:
Participant gender:
Summary
This is a multicenter, double-blind, placebo-controlled, parallel-group study consisting of a
screening period of up to 4 weeks (with the exception of participants on primidone at
baseline who will be allowed 6 weeks of screening to allow for safe discontinuation).
Screening results from all patients meeting the eligibility requirements will be further
assessed by the sponsor medical personnel for final approval of suitability for inclusion in
the study. Randomized participants will enter a 4 week double-blind dose-titration treatment
period, followed by a 1 week safety follow-up period following the last dose of study
medication, and a scheduled follow-up safety telephone call one week later.